Dr. Reddy’s Eyes Canada Nod for Semaglutide Launch Ahead of Patent Expiry

Dr. Reddy’s Laboratories Ltd. expects to receive approval from Canadian authorities for its anti-diabetic and weight-loss drug Semaglutide within the next two days, ahead of the drug’s patent expiry in January.

The company plans to roll out the product across markets including Canada, India, Turkey, and others once the patent for Semaglutide—an injectable medication that mimics the hormone glucagon-like peptide-1 (GLP-1)—expires on January 4.

A company executive said they are close to crossing the required milestones for a Canadian launch but added that traditional queries from the regulator could cause a short delay.

Dr. Reddy’s is also awaiting approval from the Drugs Controller General of India to introduce the drug domestically and expects clearance in the normal course. The company aims to launch the product in India immediately after the patent expires.